Hoffmann-la Roche Inc.

Remynd Nv

Basilea Pharmaceutica Ag

Siena Biotech S.p.a.

Unversität Zürich

Eidgenössische Technische Hochschule Zürcih

F. Hoffmann-la Roche Ag

Eidgenossische Technische Hochschule Zurich

Mark Rogers-Evans

Matthias Heinrich Nettekoven

Hasane Ratni

Caterina Bissantz

Patrick Schnider

Christophe Grundschober

Uwe Grether

Raffaello Masciadri

Emmanuel Pinard

Stephan Roever

Atsushi Kimbara

Olivier Roche

Wolfgang Guba

Thomas Johannes Woltering

Henner Knust

Tanja Schulz-Gasch

Hans Hilpert

Jens-Uwe Peters

Didier Rombach

Luca Claudio Gobbi

Wolfgang Haap

Harald Mauser

Wolfgang Wostl

Ulrike Obst Sander

Alexander Mayweg

David Banner

Bjoern Bartels

Cosimo Dolente

Robert Narquizian

Gerard Griffioen

Katrien Princen

Fabienne Ricklin

Andreas Kuglstatter

Konrad H Bleicher

Walter Vifian

Roland Humm

Christian Schnider

Parichehr Malherbe

Eoin Power

Roger Wermuth

Koen De Witte

Emilie Blanche

Bart De Taeye

Bernd Kuhn

Jean-Marc Plancher

Paul Hebeisen

Alexander Alanine

Thomas Luebbers

Markus Rudolph

Matthias Koerner

Hans Iding

Beat Wirz

Erwin Goetschi

Jean-Michel Adam

Giuseppe Cecere

Christoph Ullmer

Daniela Alberati

Emanuele Gabellieri

Sebastien Schmitt

Beat Frei

Dagmar Kube

Baledi Dhurwasulu

Stefanie Bendels

Roever Stephan

Gisbert Schneider

Jochen Zuegge

Olivier Gavelle

Roland Jakob-Roetne

Andrew William Thomas

Zhiwei Wang

Benoit Hornsperger

Rosa Maria Rodriguez Sarmiento

Rosa Maria Rodriguez-Sarmiento

Paul Spurr

Simon Mensah Ametamey

Pius Waldmeier

Fabienne Hoffmann-Emery

Helmut Werner Stahr

Alexander V Mayweg

Bernd Puellmann

Marco Prunotto

Lilli Anselm

Matthias Valentin Westphal

Goesta Rimmler

Thomas Hartung

Matteo Andreini

Massimiliano Travagli

Alessandra Polara

Philipp Cueni

Qingping Liu

Juergen Fingerle

Sébastien Schmitt

Nettekoven Matthias

Ricklin Fabienne

Anindya Hazra

Wulun Yang

Ernst Schaffter

Michela Valacchi

Ahmed Haider

The invention relates to a compound of formula (I) wherein Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Phenyl derivatives as cannabinoid receptor 2 agonists

The invention relates to compound of formula (I) wherein Rto Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Pyridine derivatives

The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

Pyridyl-triazabicycles

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R, R, R, L, L, L, L, Land n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders. 

Oxadiazole compounds

The invention relates to a compound of formula (I) wherein A and Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

The present invention relates to a compound of formula (I) wherein Ris defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Radiolabeled cannabinoid receptor 2 ligand

The invention relates to a compound of formula (I) 

Triazolo[4,5-D]pyrimidines

The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. 

BACE1 inhibitors

The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. 

2,2,2-trifluoroethyl-thiadiazines

The present invention relates to a compound of formula (IA), wherein Gis lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is &#x2014;NRR; Ris hydrogen or lower alkyl; Ris lower alkyl; tetrahydropyran-4-yl; &#x2014;CH-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or Rand Rform together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is &#x2014;CH&#x2014; or &#x2014;(CH)&#x2014;; Ar is phenyl or pyridinyl; Ris halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a stereoisomeric form, including an individual diastereoisomer or enantiomer of the compound of formula (IA) as well as to a racemic or non-racemic mixture thereof. The present invention also relates to the use of a compound of formula (IA) for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or aggregation. 

Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease

The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R, R, R, L, L, L, L, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders. 

2,7-diazaspiro[3.5]nonane compounds

The invention relates to a compound of formula (I) wherein Ato Aand Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Pyrazol derivatives

Growing community of inventors

Bottmingen, Switzerland

Mark Rogers-Evans